What is the recommended dose of faropenem (generic name) for a 4-month-old infant weighing 7.5 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Faropenem Dosing for 4-Month-Old Infant (7.5 kg)

The recommended dose of faropenem for a 4-month-old infant weighing 7.5 kg is 37.5 mg three times daily (total daily dose: 112.5 mg/day), calculated at 15 mg/kg/day divided into three doses. 1, 2

Standard Pediatric Dosing

  • The established clinical dose for faropenem in pediatric patients is 15 mg/kg/day divided into three doses 1
  • For a 7.5 kg infant, this translates to:
    • 37.5 mg per dose, administered three times daily
    • Total daily dose: 112.5 mg/day 1

Formulation and Administration

  • Faropenem is available as an oral dry syrup specifically formulated for pediatric use 1, 2
  • The medication should be administered three times daily at approximately 8-hour intervals 2
  • Treatment duration typically ranges from 3 to 8 days for most infections, though Group A streptococcal infections may require 5 to 14 days 2

Clinical Efficacy in Young Children

  • Clinical studies have demonstrated 90-94% efficacy in pediatric patients with upper respiratory tract infections and otitis media 2
  • The drug shows potent antibacterial activity against penicillin-resistant Streptococcus pneumoniae (PRSP), a critical pathogen in this age group 2
  • Faropenem has a high bacteriological eradication rate against S. pneumoniae 2

Safety Profile in Infants

  • The most common adverse effect is diarrhea, occurring in 12.5% of pediatric patients, with an incidence similar to other oral beta-lactam antibiotics 2
  • No serious adverse drug reactions have been reported in pediatric studies 2
  • Compliance is generally excellent due to the palatability of the dry syrup formulation 2

Important Clinical Considerations

  • Faropenem is stable against β-lactamase and has a low propensity for bacterial resistance 1
  • The drug has a broad spectrum of activity against both Gram-positive and Gram-negative organisms, as well as anaerobes 1, 3
  • However, faropenem is not active against methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa 4

Monitoring Response

  • Children on appropriate antibiotic therapy should demonstrate clinical improvement within 48-72 hours 5
  • If no improvement occurs within this timeframe, reevaluation and consideration of alternative therapy is necessary 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.